Author | Date | Target | Main authors specialty | Other specialty involved | Based on | Scope |
Drake et al19 | 1996 | IIMs as a whole | Dermatology | None | Evidence (grade C–D) | Treatment (overall) |
Bril et al16 | 1999 | IIMs as a whole | Neurology | None | Eminence | Treatment (IVIG) |
Doria et al18 | 2004 | Adult IIMs | Rheumatology | Neurology | Eminence | Pregnancy |
Feasby et al21 | 2007 | IIMs as a whole | Neurology | None | Evidence (grade B–D) | Treatment (IVIG) |
Alexanderson et al15 | 2007 | IIMs as a whole | Rheumatology | Physical therapy | Eminence | Disease measurement (tools) |
Donofrio et al17 | 2009 | Adult IIMs | Neurology | None | Evidence (grade B–D) | Treatment (IVIG) |
Hengstman et al23 | 2009 | IIMs as a whole | Neurology | None | Eminence | Treatment (overall) |
Titulaer et al32 | 2011 | IIMs as a whole | Neurology | None | Evidence (grade C–D) | Tumour screening |
Patwa et al29 | 2012 | Adult IIMs | Neurology | None | Evidence (grade B–D) | Treatment (IVIG) |
Sunderkotter et al31 | 2016 | IIMs as a whole | Neurology | Dermatologist | Eminence | General management |
Enk et al14 | 2016 | IIMs as a whole | Dermatology | None | Eminence | Treatment (IVIG) |
Fujimoto et al22 | 2016 | IIMs as a whole | Dermatology | None | Evidence (grade C–D) | Treatment (skin disease) |
Morrisset et al28 | 2016 | Adult IIMs | Pneumology | None | Eminence | Lung disease |
Enders et al20 | 2017 | Juvenile IIMs | Rheumatology | None | Evidence (grade B–D) | General management |
Evidence was graded according to Grading of Recommendations Assessment, Development and Evaluation Working Group 2007 (http://www.gradeworkinggroup.org/)
CPG: clinical practice guideline;IIM: idiopathic inflammatory myopathy; IVIG: intravenous immunoglobulin;